Evidence map›Paper›PMID 32227280›Full record

ArticleInternational journal of computer assisted radiology and surgery2020

Pre-clinical evaluation of an image-guided in-situ Raman spectroscopy navigation system for targeted prostate cancer interventions.

Roozbeh Shams, Fabien Picot, David Grajales, Guillaume Sheehy, Frederick Dallaire, Mirela Birlea, Fred Saad, Dominique Trudel, Cynthia Menard, Frederic Leblond and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of computer assisted radiology and surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Current Trends of Raman Spectroscopy in Clinic Settings: Opportunities and Challenges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Roozbeh ShamsPolytechnique Montreal, Montreal, Canada.
Fabien PicotPolytechnique Montreal, Montreal, Canada.
David GrajalesPolytechnique Montreal, Montreal, Canada.
Guillaume SheehyPolytechnique Montreal, Montreal, Canada.
Frederick DallairePolytechnique Montreal, Montreal, Canada.
Mirela BirleaCentre Hospitalier de l'Universite de Montreal Research Center, Montreal, Canada.
Fred SaadCentre Hospitalier de l'Universite de Montreal Research Center, Montreal, Canada.
Dominique TrudelCentre Hospitalier de l'Universite de Montreal Research Center, Montreal, Canada.
Cynthia MenardCentre Hospitalier de l'Universite de Montreal Research Center, Montreal, Canada.
Frederic LeblondPolytechnique Montreal, Montreal, Canada.
Samuel KadouryPolytechnique Montreal, Montreal, Canada. samuel.kadoury@polymtl.ca.ORCID http://orcid.org/0000-0002-3048-4291
Polytechnique Montréal · CACentre Hospitalier de l’Université de Montréal · CA

Funding

CIHR MOP-89921
6 · The paper itself

Abstract

purposeTransrectal ultrasound (TRUS) image guidance is the standard of care for diagnostic and therapeutic interventions in prostate cancer (PCa) patients, but can lead to high false-negative rates, compromising downstream effectiveness of therapeutic choices. A promising approach to improve in-situ detection of PCa lies in using the optical properties of the tissue to discern cancer from healthy tissue. In this work, we present the first in-situ image-guided navigation system for a spatially tracked Raman spectroscopy probe integrated in a PCa workflow, capturing the optical tissue fingerprint. The probe is guided with fused TRUS/MR imaging and tested with both tissue-simulating phantoms and ex-vivo prostates. The workflow was designed to be integrated the clinical workflow for trans-perineal prostate biopsies, as well as for high-dose rate (HDR) brachytherapy.

methodsThe proposed system developed in 3D Slicer includes an electromagnetically tracked Raman spectroscopy probe, along with tracked TRUS imaging automatically registered to diagnostic MRI. The proposed system is tested on both custom gelatin tissue-simulating optical phantoms and biological tissue phantoms. A random-forest classifier was then trained on optical spectrums from ex-vivo prostates following prostatectomy using our optical probe. Preliminary in-human results are presented with the Raman spectroscopy instrument to detect malignant tissue in-situ with histopathology confirmation.

resultsIn 5 synthetic gelatin and biological tissue phantoms, we demonstrate the ability of the image-guided Raman system by detecting over 95% of lesions, based on biopsy samples. The included lesion volumes ranged from 0.1 to 0.61 cc. We showed the compatibility of our workflow with the current HDR brachytherapy setup. In ex-vivo prostates of PCa patients, the system showed a 81% detection accuracy in high grade lesions.

conclusionPre-clinical experiments demonstrated promising results for in-situ confirmation of lesion locations in prostates using Raman spectroscopy, both in phantoms and human ex-vivo prostate tissue, which is required for integration in HDR brachytherapy procedures.

Indexed as

BiopsyHumansImage-Guided BiopsyMagnetic Resonance ImagingMalePhantoms, ImagingProstatectomyProstatic NeoplasmsSpectrum Analysis, RamanUltrasonographyImage-guided biopsyProstate cancerRaman spectroscopyTRUS/MRI fusion

Identifiers

PMID32227280
OpenAlexW3013252936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.